Rspondins as modulators of angiogenesis and vasculogenesis

Patent metadata

Field	Value
Publication number	US-10538563-B2
Application number	US-201916357765-A
Country	US
Kind code	B2
Filing date	Mar 19, 2019
Priority date	Oct 20, 2006
Publication date	Jan 21, 2020
Grant date	Jan 21, 2020

Abstract

The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 arc angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signaling system during angiogenesis. The invention also relates to the use of regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis.

First claim

The invention claimed is:

1. A method for inhibiting angiogenesis and/or vasculogenesis in a subject in need of such treatment comprising administering to the subject a therapeutically effective dose of an Rspondin2 antagonist, wherein the Rspondin2 antagonist is a nucleic acid molecule capable of inhibiting Rspondin2 translation, transcription, expression and/or activity.

2. The method of claim 1 , wherein the Rspondin2 antagonist is an antisense molecule or siRNA molecule.

3. The method of claim 1 , wherein the Rspondin2 antagonist is an antisense molecule capable of inhibiting transcription of Rspondin2 nucleic acid encoding Rspondin2 polypeptide comprising the amino acid sequence set out in SEQ ID NO:19 or an amino acid sequence having at least 90% identity to SEQ ID NO:19 or capable of inhibiting translation, expression and/or activity of Rspondin2 polypeptide comprising the amino acid sequence set out in SEQ ID NO:19 or an amino acid sequence having at least 90% identity to SEQ ID NO:19.

Assignees

• Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
• Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Inventors

• Niehrs Christof
• Kazanskaya Olga
• Okawara Bisei

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/08

  Vasodilators for multiple indications · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title